source
- Capricor plans FDA amendment after advisory committee rejects cardiomyopathy endpoint, stock jumpsCapricor Therapeutics received a negative vote from an FDA advisory committee on the efficacy of its cell therapy, deramiocel, for treating cardiomyopathy in Duchenne muscular dystrophy. The nine‑t…
- Jazz Pharmaceuticals to acquire Actio Biosciences in deal worth over $1.3 billionJazz Pharmaceuticals announced an agreement to purchase Actio Biosciences, a San Diego biotech focused on genetic epilepsies. The transaction could total just over $1.3 billion, with $820 million…